Physician profile
Max J Glaser
NPI 1750370615
$1,640.45
in general payments reported to CMS, 2019-2025
13 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $20.03 · 2021: $267 · 2022: $538 · 2023: $338 · 2024: $99.18 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $854.90 | 2019-2025 | Covera |
| Medtronic, INC. | $255.11 | 2021-2023 | Chameleon |
| Mozarc Medical US LLC | $254.40 | 2023-2025 | Chameleon, Palindrome |
| Boston Scientific Corporation | $99.13 | 2019-2021 | |
| Amgen INC. | $35.84 | 2022-2025 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $22.74 | 2022 | |
| Vifor Pharma, INC. | $20.39 | 2023 | Veltassa, Korsuva |
| Novo Nordisk INC | $19.38 | 2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.65 | 2024 | Jardiance |
| Horizon Therapeutics Plc | $16.38 | 2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $16.33 | 2021 | |
| La Jolla Pharmaceutical Company | $14.70 | 2019 | |
| G Medical Diagnostic Services, INC. | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Glaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.